| Primary |
| Drug Use For Unknown Indication |
42.6% |
| Product Used For Unknown Indication |
20.4% |
| Anaesthesia |
13.0% |
| Pain |
7.4% |
| Sedation |
7.4% |
| Analgesic Therapy |
3.7% |
| Hypotonia |
1.9% |
| Laryngeal Oedema |
1.9% |
| Sedative Therapy |
1.9% |
|
| Dependence |
12.5% |
| Ileus Paralytic |
12.5% |
| Pneumonia Aspiration |
12.5% |
| Somnolence |
12.5% |
| Delirium |
6.3% |
| Fall |
6.3% |
| Foetal Death |
6.3% |
| Hypotension |
6.3% |
| Neuroleptic Malignant Syndrome |
6.3% |
| Oxygen Saturation Decreased |
6.3% |
| Respiratory Depression |
6.3% |
| Sedation |
6.3% |
|
| Secondary |
| Prophylaxis |
10.9% |
| Product Used For Unknown Indication |
9.4% |
| Analgesic Effect |
7.2% |
| Analgesia |
6.5% |
| Hepatic Neoplasm Malignant |
6.5% |
| Peritonitis |
6.5% |
| Epidural Anaesthesia |
5.8% |
| Infection Prophylaxis |
5.8% |
| Abdominal Pain |
4.3% |
| Graft Versus Host Disease |
4.3% |
| Pain |
4.3% |
| Sedation |
4.3% |
| Infection |
3.6% |
| Anaesthetic Premedication |
2.9% |
| Convulsion Prophylaxis |
2.9% |
| General Anaesthesia |
2.9% |
| Insomnia |
2.9% |
| Premedication |
2.9% |
| Prophylaxis Against Graft Versus Host Disease |
2.9% |
| Stem Cell Transplant |
2.9% |
|
| Blood Bilirubin Increased |
17.6% |
| Liver Disorder |
17.6% |
| Nausea |
17.6% |
| Rhabdomyolysis |
17.6% |
| Weight Increased |
11.8% |
| Sick Sinus Syndrome |
5.9% |
| Toxic Epidermal Necrolysis |
5.9% |
| Vomiting |
5.9% |
|
| Concomitant |
| Drug Use For Unknown Indication |
13.3% |
| Sedation |
12.1% |
| Fluid Replacement |
10.3% |
| Prophylaxis |
8.6% |
| Infection |
7.2% |
| Ureteral Stent Insertion |
4.7% |
| Ureteral Stent Removal |
4.7% |
| Pyrexia |
4.0% |
| Product Used For Unknown Indication |
3.9% |
| Diuretic Therapy |
3.8% |
| Insomnia |
3.7% |
| Pain |
3.4% |
| Hypertension |
3.3% |
| Infection Prophylaxis |
3.2% |
| Electrolyte Substitution Therapy |
2.8% |
| Mineral Supplementation |
2.8% |
| Cardiac Failure |
2.4% |
| Shock |
2.0% |
| Prophylaxis Against Graft Versus Host Disease |
2.0% |
| Anticoagulant Therapy |
1.9% |
|
| Respiratory Failure |
13.8% |
| Renal Impairment |
10.1% |
| Pancytopenia |
7.3% |
| Toxic Epidermal Necrolysis |
7.3% |
| Multi-organ Failure |
5.5% |
| Rhabdomyolysis |
5.5% |
| Thrombocytopenia |
5.5% |
| White Blood Cell Count Decreased |
5.5% |
| Injection Site Ulcer |
4.6% |
| Superinfection |
4.6% |
| Liver Disorder |
3.7% |
| Staphylococcal Sepsis |
3.7% |
| Ventricular Tachycardia |
3.7% |
| Electrocardiogram Qt Prolonged |
2.8% |
| Pain In Extremity |
2.8% |
| Pyrexia |
2.8% |
| Thrombotic Thrombocytopenic Purpura |
2.8% |
| Tongue Oedema |
2.8% |
| Transplant Rejection |
2.8% |
| Ventricular Fibrillation |
2.8% |
|
